Biliary Tract Cancer Market Size is anticipated to Grow with a significant CAGR by 2036, estimates DelveInsight

DelveInsight's "Biliary Tract Cancer Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology, as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Biliary Tract Cancer Market Share @ Biliary Tract Cancer Market Outlook- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Biliary Tract Cancer Market Report
• In January 2026, TransThera Sciences announced presentation of tinengotinib monotherapy in patients with advanced CCA at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026.
• In the 7MM, Japan recorded the highest number of Incident cases of BTC accounting for ~22,000 cases in 2025, which are expected to continue increasing at a CAGR of 1.2%
• Among the EU4 and the UK, Italy accounted for the highest number of BTC cases, followed by the UK and Germany, whereas Spain accounted for the lowest number of cases in 2025.
• BTC represent a rare but highly lethal group of malignancies in the 7MM, with CCA accounting for a substantial proportion of cases and disease burden. The epidemiology of CCA is heterogeneous across the 7MM, reflecting regional differences in underlying risk factors, healthcare access, diagnostic practices, and disease classification.
• Japan demonstrates a consistently higher disease burden compared with Western markets, likely driven by a greater prevalence of biliary tract disorders and long-standing clinical recognition of BTC.
• The leading Biliary Tract Cancer Companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
• Promising Biliary Tract Cancer Pipeline Therapies such as Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.

Stay ahead in the Biliary Tract Cancer Therapeutics Market with DelveInsight's Strategic Report @ Biliary Tract Cancer Treatment Market- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Epidemiology Segmentation in the 7MM
• Total Biliary Tract Cancer Incident Cases
• Biliary Tract Cancer Age-specific Cases
• Biliary Tract Cancer Stage-specific Cases
• Total Incident Cases of Biliary Tract Cancer by tumor location in the 7MM
• Biliary Tract Cancer Mutation-specific Cases
• Biliary Tract Cancer Treated Cases

Download the report to understand which factors are driving Biliary Tract Cancer Epidemiology trends @ Biliary Tract Cancer Prevalence- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Marketed Drugs
• Pemigatinib (PEMAZYRE): Incyte
Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. In August 2025, Incyte discontinued the Phase III FIGHT-302 trial evaluating a first-line therapy for unresectable or metastatic FGFR2-rearranged cholangiocarcinoma due to poor enrollment following a shift in the standard of care. Patent expiry is expected between 2035 and 2040.

• Entrectinib (ROZLYTREK): Roche/Genentech
Entrectinib is an oral tyrosine kinase inhibitor used in adults and children (>1 month) with metastatic or unresectable solid tumors harboring NTRK gene fusions or ROS1 fusions. It blocks TRK A/B/C and ROS1 kinase activity to inhibit cancer cell growth and induce tumor cell death. Marketed as ROZLYTREK, its patent expiry is expected to begin around 2028.

Biliary Tract Cancer Emerging Drugs
• Tinengotinib : TransThera Sciences
Tinengotinib, is an investigational oral multi-kinase inhibitor for cholangiocarcinoma, especially in patients with FGFR-altered tumors who progressed after prior therapy. It targets FGFR1-3, VEGFR, Aurora, and JAK kinases, helping suppress tumor growth, angiogenesis, and resistance. Data were presented at the ASCO Gastrointestinal Cancers Symposium 2026, with a US launch anticipated in 2027.

• Rilvegostomig: AstraZeneca
Rilvegostomig is a first-in-class dual-checkpoint bispecific antibody providing PD-1 and TIGIT blockade on the same immune cell to restore antitumor immunity and enable durable responses. Its TIGIT component is derived from COM902, developed by Compugen. In December 2025, Compugen reached an agreement with AstraZeneca to monetize part of its future royalties and amended their 2018 exclusive licensing deal to support its immuno-oncology pipeline.

To learn more about Biliary Tract Cancer Treatment guidelines, visit @ Biliary Tract Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Companies
Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.

Biliary Tract Cancer Market Outlook
BTC is a heterogeneous group of invasive adenocarcinomas including iCCA, eCCA, GBC, and ampullary carcinoma. Prognosis remains poor, with an overall 5-year survival rate of ~15%, dropping to ~8.5% for iCCA, particularly in patients with metastatic disease. Curative treatment relies on surgical resection followed by adjuvant capecitabine, though recurrence rates are high. For advanced or unresectable BTC, first-line therapy typically includes Cisplatin + Gemcitabine, while second-line options include 5-Fluorouracil-based regimens such as FOLFOX regimen or irinotecan combinations. Recent advances in precision oncology have introduced targeted therapies for molecular alterations including FGFR2 fusions, IDH1 mutations, BRAF V600E, NTRK fusions, HER2 amplification, and MSI-H, shifting treatment toward biomarker-driven approaches, particularly in iCCA.Larotrectinib became the first therapy approved that included BTC under a tumor-agnostic indication for NTRK gene fusion-positive solid tumors. This marked the first regulatory breakthrough beyond chemotherapy in BTC.In 2019, entrectinib, developed by Roche/Genentech, was approved for NTRK fusion-positive solid tumors, including BTC. Entrectinib demonstrated a stronger efficacy signal (ORR ~46% across solid tumors), reinforcing the validity of molecularly driven treatment strategies.

Biliary Tract Cancer Treatment Market
The biliary tract comprises of gallbladder and intra and extrahepatic biliary tree. Bile is directed through these ducts to the second part of duodenum at major duodenal papilla. The epithelium of the biliary tract is lined with cells called cholangiocytes. Carcinoma of the biliary tract arises from the malignant transformation of the epithelium of the bile ducts which is made up of these cholangiocytes, and is categorized on the basis of its anatomical location as; 1) Intrahepatic cholangiocarcinoma 2) Extrahepatic cholangiocarcinoma, which includes; perihilar tumor also known as Klatskin tumor (originating from the epithelium of the bile duct at the junction of right and left hepatic ducts with the cystic duct where it forms the common bile duct) and distal cholangiocarcinoma outspreading to encompass the gallbladder, ampulla of Vater and pancreatic biliary ducts.

Learn more about the FDA-approved drugs for Biliary Tract Cancer @ Drugs for Biliary Tract Cancer Treatment- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Biliary Tract Cancer Market Report
• Coverage- 7MM
• Study Period0- 2022-2036
• Biliary Tract Cancer Companies- Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
• Biliary Tract Cancer Pipeline Therapies- Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.
• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer Market Drivers and Barriers
• Biliary Tract Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Biliary Tract Cancer (BTC)
4. Key Events
5. Biliary Tract Cancer Market Overview at a Glance
6. Disease Background and Overview
7. Current Treatment Practices of Biliary Tract Cancer
8. Guidelines: Diagnosis and Treatment
9. Biliary Tract Cancer Epidemiology and Market Forecast Methodology
10. Biliary Tract Cancer Epidemiology and Patient Population
11. Biliary Tract Cancer Patient Journey
12. Marketed Biliary Tract Cancer Therapies
13. Emerging Biliary Tract Cancer Therapies
14. Biliary Tract Cancer (BTC) Market Analysis
15. Biliary Tract Cancer Unmet Needs
16. Biliary Tract Cancer SWOT Analysis
17. KOL Views
18. Biliary Tract Cancer Market Access and Reimbursement
19. Biliary Tract Cancer Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.